The distal hinge of the reactive site loop and its proximity - A target to modulate plasminogen activator inhibitor-1 activity

被引:37
作者
Bijnens, AP
Gils, A
Stassen, JM
Komissarov, AA
Knockaert, I
Brouwers, E
Shore, JD
Declerck, PJ
机构
[1] Katholieke Univ Leuven, Fac Pharmaceut Sci, Lab Pharmaceut Biol & Phytopharmacol, B-3000 Louvain, Belgium
[2] Boehringer Ingelheim Pharma KG, Cardiovasc Pharmacol, D-88397 Biberach, Germany
[3] Henry Ford Hlth Ctr, Div Biochem Res, Detroit, MI 48202 USA
关键词
D O I
10.1074/jbc.M103077200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serpin plasminogen activator inhibitor type 1 (PAI-1) plays a regulatory role in various physiological processes (e.g. fibrinolysis and pericellular proteolysis) and forms a potential target for therapeutic interventions. In this study we identified the epitopes of three PAI-1 inhibitory monoclonal antibodies (MA-44E4, MA-42A2F6, and MA-56A7C10). Differential cross-reactivities of these monoclonals with PAI-1 from different species and sequence alignments between these PAI-1s, combined with the three-dimensional structure, revealed several charged residues as possible candidates to contribute to the respective epitopes. The production, characterization, and subsequent evaluation of a variety of alanine mutants using surface plasmon resonance revealed that the residues His(185), Arg(186), and Arg(187) formed the major sites of interaction for MA-44E4. In contrast, the epitopes of MA-42A2F6 and MA-56A7C10 were found to be conformational. The epitope of MA-42A2F6 comprises residues Lys(243) and Glu(350), whereas the epitope of MA-56A7C10 comprises residues Glu(242), Lys(243), Glu(244), Glu(350) Asp(355) and Arg(356). The participation of Glu(350), Asp(355), and Arg(356) provides a molecular explanation for the differential exposure of this epitope in the different conformations of PAI-1 and for the effect of these antibodies on the kinetics of the formation of the initial PAI-1-proteinase complexes. The localization of the epitopes of MA-44E4, MA42A2F6, and MA-56A7C10 elucidates two previously unidentified molecular mechanisms to modulate PAI-1 activity and opens new perspectives for the rational development of PAI-1 neutralizing compounds.
引用
收藏
页码:44912 / 44918
页数:7
相关论文
共 57 条
  • [1] MECHANISMS CONTRIBUTING TO THE CONFORMATIONAL AND FUNCTIONAL FLEXIBILITY OF PLASMINOGEN-ACTIVATOR INHIBITOR-1
    AERTGEERTS, K
    DEBONDT, HL
    DERANTER, CJ
    DECLERCK, PJ
    [J]. NATURE STRUCTURAL BIOLOGY, 1995, 2 (10): : 891 - 897
  • [2] PLASMINOGEN-ACTIVATOR INHIBITOR TYPE-1 - REACTIVE CENTER AND AMINO-TERMINAL HETEROGENEITY DETERMINED BY PROTEIN AND CDNA SEQUENCING
    ANDREASEN, PA
    RICCIO, A
    WELINDER, KG
    DOUGLAS, R
    SARTORIO, R
    NIELSEN, LS
    OPPENHEIMER, C
    BLASI, F
    DANO, K
    [J]. FEBS LETTERS, 1986, 209 (02) : 213 - 218
  • [3] ASAKURA S, 1990, J BIOL CHEM, V265, P5135
  • [4] ASAKURA S, 1989, J BIOL CHEM, V264, P13736
  • [5] AUDENAERT AM, 1994, J BIOL CHEM, V269, P19559
  • [6] Importance of the hinge region between α-helix F and the main part of serpins, based upon identification of the epitope of plasminogen activator inhibitor type 1 neutralizing antibodies
    Bijnens, AP
    Gils, A
    Knockaert, I
    Stassen, JM
    Declerck, PJ
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (09) : 6375 - 6380
  • [7] Bijnens AP, 1997, THROMB HAEMOSTASIS, V77, P350
  • [8] Bijnens AP, 2001, THROMB HAEMOSTASIS, V85, P866
  • [9] Epitopes on plasminogen activator inhibitor type-1 important for binding to tissue plasminogen activator
    Bjorquist, P
    Ehnebom, J
    Inghardt, T
    Deinum, J
    [J]. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 1997, 1341 (01): : 87 - 98
  • [10] Blasi F, 1999, THROMB HAEMOSTASIS, V82, P298